Head-to-head evidence
Dalpiciclib vs Ribociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Dalpiciclib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06009627 · Phase 2/3 · completed
The trial randomized 119 participants to an active chemotherapy comparator and used investigator masking, but it was not double-blind. Its primary endpoint was objective tumor response rate, and no primary endpoint results or statistical comparison have been posted, so the outcome cannot be judged as met or missed.
Next expected readout: October 2026 · NCT04842617 (registry estimate)
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalpiciclib's landscape · Ribociclib's landscape